Ralph Henry, PhD
VP Life Science and Medical Technology
Dr. Henry recently moved to the Dallas-Ft. Worth area from Fayetteville, AR where he was Distinguished Professor and held the WM Keck Professorship at the University of Arkansas.
As a faculty member in the Biological Sciences Department and the Institute for Nano-scale Science and Engineering, he directed a federally funded research program for 21 years, which focused on protein targeting, protein production technologies, and development of protein therapies to treat methamphetamine addiction.
Dr. Henry’s work at the university produced over 50 publications and 5 patents, which currently support the IP portfolio of two different Arkansas-based biotech companies. Also is co-founder and VP Biopharmaceutics at InterveXion Therapeutics where his efforts support interactions with FDA, manufacturing and testing of InterveXion’s protein therapies, and oversight of these therapies for Phase 1 (completed) and Phase 2 (upcoming) human clinical trials.
- Antibody-based and other protein-based therapeutics and vaccines
- Non-opioid and non-addictive therapeutics to treat pain and inflammation
- Regenerative medicine, materials, and devices to treat soft-tissue joint injury